Examination, performance indicators and complications on discharge of patients who had an AIS and HS
| Indicators | AS | HS | ||
| Number | Per cent | Number | Per cent | |
| TTE examination | 57 | 33.14 | 13 | 9.29 |
| Abnormal TTE | 12/57 | 21.05 | 1 | 7.69 |
| Bubble study | 5 | 2.91 | 0 | 0 |
| Positive bubble study | 2/5 | 40.00 | 0 | 0 |
| TCD examination | 12 | 6.98 | 2 | 1.42 |
| Examination of CT scan of the brain | 147 | 85.47 | 133 | 95.00 |
| MRI examination of the brain | 162 | 94.19 | 125 | 89.29 |
| MRA examination of the brain | 64 | 37.21 | 14 | 8.57 |
| CTA of the head | 77 | 44.77 | 18 | 10.00 |
| DSA of the head | 125 | 52.90 | 83 | 59.28 |
| Abnormal DSA | 121/125 | 96.8 | 66/83 | 79.51 |
| Acute treatment | ||||
| Thrombolysis | 0 | 0 | – | – |
| Antithrombotic | 30 | 17.44 | – | – |
| Anticoagulant | 9 | 5.23 | – | – |
| Neuroprotective agents | 50 | 29.07 | 22 | 15.71 |
| Antiepileptic drug | 93 | 54.07 | 53 | 37.86 |
| Discharge medication | ||||
| Antithrombotic | ||||
| Aspirin | 9 | 5.23 | – | – |
| Clopidogrel | 2 | 1.16 | – | – |
| Anticoagulant | ||||
| Warfarin | 2 | 1.16 | – | – |
| Antiepileptic drug | 38 | 22.09 | 24 | 17.14 |
| Complication | ||||
| Epilepsy | 38 | 22.09 | 24 | 17.14 |
| Hydrocephalus | 0 | 0 | 17 | 12.14 |
| Deep venous thrombus | 0 | 0 | 0 | 0 |
| Pneumonia | 8 | 4.65 | 13 | 9.29 |
| Cerebral hernia | 0 | 0 | 3 | 2.14 |
| Infection of CNS | 2 | 1.16 | 6 | 4.29 |
| Electrolyte disturbance | 1 | 0.58 | 13 | 9.29 |
| Neurological deficits | ||||
| Movement | 77 | 44.77 | 59 | 42.14 |
| Speech | 13 | 7.56 | 11 | |
| hearing | 1 | 0.58 | 1 | 0.71 |
| Vision | 4 | 2.33 | 4 | 2.86 |
| Cognitive | 5 | 2.91 | 2 | 1.43 |
| Epilepsy | 38 | 22.09 | 24 | 17.14 |
| Feelling | 1 | 0.58 | 1 | 0.71 |
| Memory | 0 | 0 | 0 | 0 |
AIS, arterial ischaemic stroke; CNS, central nervous system; CTA, computed tomographic angiography; DSA, digital angiography; HS, haemorrhagic stroke; MRA, magnetic resonance angiography; TCD, transcranial Doppler; TTE, transthoracic echocardiogram.